Loading clinical trials...

RECRUITINGPHASE1

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

NCT06945419•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Have no significant body weight change for the 3 months prior to screening
•Part A and Part E:
•Are considered healthy
•Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
•Part B:
•Have a BMI of 27 to 45 kg/m2 at screening
•Part C:
•Have a BMI of 25 to 45 kg/m2 at screening
•Part D:
•Have type 2 diabetes
+2 more criteria

Exclusion Criteria

•Have had an acute cardiovascular condition within the past 6 months prior to screening
•Have liver disease or pancreatitis
•Have used medications for weight loss within the 3 months prior to screening
•Parts A, B, C, E:
•Have any form of diabetes
•Part D:
•Have type 1 diabetes

Locations (5)

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Clinical Pharmacology of Miami

Miami, Florida, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States

Endeavor Clinical Trials

San Antonio, Texas, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

Key Dates

Start Date

April 23, 2025

Primary Completion Date

April 1, 2026

Completion Date

April 1, 2026

Last Updated

March 2, 2026

Enrollment

201

ESTIMATED participants

Conditions

HealthyOverweightObesityType 2 Diabetes

Interventions

LY4086940

DRUG

Placebo

DRUG

LY4086940

DRUG

Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

1-317-615-4559 LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

CONTACT

clinical_inquiry_hub@lilly.com

Collection of Data and Samples From Healthy Donors for Use in Translational Research

NCT00090662

Healthy Volunteer

View study

RECRUITINGPHASE1/PHASE2

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

NCT06290258

Autism Spectrum DisorderGastrointestinal Diseases+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Inclusion Criteria

Exclusion Criteria

Collection of Data and Samples From Healthy Donors for Use in Translational Research

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

A New Portable Device for Non-invasive Ventilatory Support

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women